Anny Xiang to Chromans
This is a "connection" page, showing publications Anny Xiang has written about Chromans.
Connection Strength
0.865
-
Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes. J Clin Endocrinol Metab. 2005 Apr; 90(4):1986-91.
Score: 0.250
-
Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function. J Clin Endocrinol Metab. 2004 Jun; 89(6):2846-51.
Score: 0.240
-
Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes. Atherosclerosis. 2008 Jul; 199(1):207-14.
Score: 0.076
-
Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes. 2005 Nov; 54(11):3319-25.
Score: 0.066
-
Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care. 2004 Jun; 27(6):1365-8.
Score: 0.060
-
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002 Sep; 51(9):2796-803.
Score: 0.053
-
Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes. 2000 May; 49(5):782-8.
Score: 0.045
-
TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials. 1998 Apr; 19(2):217-31.
Score: 0.039
-
Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes. 1996 Nov; 45(11):1572-9.
Score: 0.035